100,000 genomes and other cancer genome sequencing projects: experiences, discoveries and future plans

Programme stream(s): Cancer discovery / underpinning research
Programme session type(s): Parallel session

Chair: Ian Tomlinson, University of Birmingham

2:00 pm-3:30 pm

Room: Boisdale

The 100,000 Genomes project (100KGP), to sequence patients with rare diseases (including cancer) and many different types of cancer is coming to a close in its current form. The project has spawned many allied activities, such as work in variant effect prediction and changes in routine histopathology practice. At least in part, the 100KGP is likely to be extended into routine clinical use. However, the project has not been cheap, and it can argued that whole genome sequencing remains overkill for most cancers. We also do not know yet whether it has provided the boost to industry and the UK Biotech sector that was one of the reasons for its inception. In this session, we compare the 100KGP with other cancer genome sequencing projects, and assess the benefits of the 100KGP, some of its early deliveries and how it should be taken forward.